Defendant
1 case as defendant.
Sinclair Pharma Limited is a global medical aesthetics company headquartered in London, United Kingdom. Founded in 1971, the company operates as a wholly-owned subsidiary of Huadong Medicine Company Limited (HMC), a Chinese pharmaceutical listed company, which acquired Sinclair Pharma in November 2018. Sinclair Pharma employs approximately 500-700 individuals and reported a revenue of £135 million as of December 31, 2022.
The company specializes in aesthetic dermatology, offering a portfolio of differentiated pharmaceutical products and technologies focused on collagen stimulation for minimally invasive treatments. Its major product lines include injectables, dermal fillers, and thread lifting solutions, marketed under brands such as Ellansé, Lanluma, MaiLi, Perfectha, and Silhouette Soft. Sinclair Pharma aims to provide high-quality, longer-duration, and natural-looking results for facial rejuvenation and contouring.
In terms of patent litigation, Sinclair Pharma Limited appears as a defendant in its single tracked case, with no instances as a plaintiff. This posture suggests that Sinclair Pharma is an operating company defending against intellectual property claims rather than actively asserting patents.
The company's sole tracked litigation, HydraFacial LLC v. Sinclair Pharma Limited et al., is recorded in the U.S. District Court for the Central District of California. This case aligns with Sinclair Pharma's operational focus on aesthetic medical devices and treatments.
This district court case by HydraFacial LLC against Sinclair Pharma Limited and others is currently active, as indicated by its listing in related IPR filings.